1. Scrip
  2. >>R&D

BioXcel's BXCL501 Data In Dementia Patients Reinforce Its Efficacy In Agitation

Company Plans Phase III Discussions In H1 2021

 
• By Alaric DeArment

Execs said data from the institutional setting could be a bridge to other settings, while the duration of response indicates a real-world benefit that could aid adoption.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
BioXcel announced Phase Ib/II data for BXCL501 in demetia-related agitation. • Source: Shutterstock

BioXcel Therapeutics, Inc. has further bolstered the case for its drug for agitation, BXCL501, with new early data in patients with dementia that support later-stage data released in the summer of 2020 in patients with agitation related to two other psychiatric conditions.

The New Haven, CT-based company announced on 5 December data from the Phase Ib/II TRANQUILITY study testing BXCL501 at three dose levels – 30mcg, 60mcg and 90mcg – against placebo in 54 patients in assisted living facilities with agitation related to dementia, 87% of whom had Alzheimer’s disease

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

More from Scrip

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.